Literature DB >> 33420219

Salivary microbiome with gastroesophageal reflux disease and treatment.

Nadia Kawar1, Seon Gyeong Park1, Joel L Schwartz2, Nicholas Callahan3, Ales Obrez4, Bin Yang4, Zhengjia Chen5,6, Guy R Adami7.   

Abstract

The effect of oral microbial composition on periodontal health and on systemic health has been, and is being established. The oral microbiome, in turn, can be altered by local and systemic diseases and conditions. Gastroesophageal reflux disease (GERD), has been associated with increased acidity in the oral cavity resulting in dental erosion, and controversially a reduced risk of periodontal disease. We hypothesized that presence of GERD was linked to a modified microbial profile in untreated GERD patients and that the use of proton pump inhibitor (PPI) drugs: potent disruptors of gut microbiome, in GERD patients might result in a salivary microbiome that is further distinct. Untreated GERD patients showed multiple differences in salivary microbiome as compared to healthy controls. Taxa found at lower levels related to the presence of GERD not treated by PPI included: Prevotella melaninogenica, Prevotella pallens, Leptotrichia, and Solobacterium moorei and thirteen others. In contrast, GERD patients chronically using PPI showed minimal differences in salivary taxa compared to healthy controls not using PPI.

Entities:  

Year:  2021        PMID: 33420219      PMCID: PMC7794605          DOI: 10.1038/s41598-020-80170-y

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  38 in total

1.  16S rRNA Gene Analysis with QIIME2.

Authors:  Michael Hall; Robert G Beiko
Journal:  Methods Mol Biol       Date:  2018

2.  Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.

Authors:  Paul Moayyedi; John W Eikelboom; Jackie Bosch; Stuart J Connolly; Leanne Dyal; Olga Shestakovska; Darryl Leong; Sonia S Anand; Stefan Störk; Kelley R H Branch; Deepak L Bhatt; Peter B Verhamme; Martin O'Donnell; Aldo P Maggioni; Eva M Lonn; Leopoldo S Piegas; Georg Ertl; Matyas Keltai; Nancy Cook Bruns; Eva Muehlhofer; Gilles R Dagenais; Jae-Hyung Kim; Masatsugu Hori; P Gabriel Steg; Robert G Hart; Rafael Diaz; Marco Alings; Petr Widimsky; Alvaro Avezum; Jeffrey Probstfield; Jun Zhu; Yan Liang; Patricio Lopez-Jaramillo; Ajay K Kakkar; Alexander N Parkhomenko; Lars Ryden; Nana Pogosova; Antonio L Dans; Fernando Lanas; Patrick J Commerford; Christian Torp-Pedersen; Tomek J Guzik; Dragos Vinereanu; Andrew M Tonkin; Basil S Lewis; Camilo Felix; Khalid Yusoff; Kaj P Metsarinne; Keith A A Fox; Salim Yusuf
Journal:  Gastroenterology       Date:  2019-05-29       Impact factor: 22.682

3.  Long-term proton pump inhibitor therapy and risk of hip fracture.

Authors:  Yu-Xiao Yang; James D Lewis; Solomon Epstein; David C Metz
Journal:  JAMA       Date:  2006-12-27       Impact factor: 56.272

4.  Oral microbiome alterations of healthy volunteers with proton pump inhibitor.

Authors:  Tsuyoshi Mishiro; Kentaro Oka; Yasutoshi Kuroki; Motomichi Takahashi; Kasumi Tatsumi; Tsukasa Saitoh; Hiroshi Tobita; Norihisa Ishimura; Shuichi Sato; Shunji Ishihara; Joji Sekine; Koichiro Wada; Yoshikazu Kinoshita
Journal:  J Gastroenterol Hepatol       Date:  2018-02-14       Impact factor: 4.029

Review 5.  Adverse effects of long-term proton pump inhibitor therapy.

Authors:  Edward Sheen; George Triadafilopoulos
Journal:  Dig Dis Sci       Date:  2011-03-02       Impact factor: 3.199

6.  Changes in the distal esophageal microbiota in Chinese patients with reflux esophagitis.

Authors:  Ying Yu; Feng Gao; Xue Chen; Shuai Zheng; Jie Zhang
Journal:  J Dig Dis       Date:  2018-12-27       Impact factor: 2.325

7.  The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus.

Authors:  Nimish Vakil; Sander V van Zanten; Peter Kahrilas; John Dent; Roger Jones
Journal:  Am J Gastroenterol       Date:  2006-08       Impact factor: 10.864

8.  DADA2: High-resolution sample inference from Illumina amplicon data.

Authors:  Benjamin J Callahan; Paul J McMurdie; Michael J Rosen; Andrew W Han; Amy Jo A Johnson; Susan P Holmes
Journal:  Nat Methods       Date:  2016-05-23       Impact factor: 28.547

9.  Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility.

Authors:  Charlie T Seto; Patricio Jeraldo; Robert Orenstein; Nicholas Chia; John K DiBaise
Journal:  Microbiome       Date:  2014-11-25       Impact factor: 14.650

10.  Oral soft tissue disorders are associated with gastroesophageal reflux disease: retrospective study.

Authors:  Masaaki Watanabe; Eiji Nakatani; Hiroo Yoshikawa; Takahiro Kanno; Yoshiki Nariai; Aya Yoshino; Michael Vieth; Yoshikazu Kinoshita; Joji Sekine
Journal:  BMC Gastroenterol       Date:  2017-08-07       Impact factor: 3.067

View more
  5 in total

1.  Editorial: The Microbiome in Hepatobiliary and Intestinal Disease.

Authors:  Phillipp Hartmann
Journal:  Front Physiol       Date:  2022-04-13       Impact factor: 4.755

2.  Investigation of the impact of commonly used medications on the oral microbiome of individuals living without major chronic conditions.

Authors:  Vanessa DeClercq; Jacob T Nearing; Morgan G I Langille
Journal:  PLoS One       Date:  2021-12-09       Impact factor: 3.240

3.  Old age and other factors associated with salivary microbiome variation.

Authors:  Joel L Schwartz; Natalia Peña; Nadia Kawar; Andrew Zhang; Nicholas Callahan; Steven J Robles; Andrew Griebel; Guy R Adami
Journal:  BMC Oral Health       Date:  2021-10-04       Impact factor: 2.757

Review 4.  Faecal Microbiota in Infants and Young Children with Functional Gastrointestinal Disorders: A Systematic Review.

Authors:  Denise Hofman; Urszula Kudla; Mohamad Miqdady; Thi Viet Ha Nguyen; Sofía Morán-Ramos; Yvan Vandenplas
Journal:  Nutrients       Date:  2022-02-25       Impact factor: 5.717

Review 5.  Oral Prevotella Species and Their Connection to Events of Clinical Relevance in Gastrointestinal and Respiratory Tracts.

Authors:  Eija Könönen; Ulvi K Gursoy
Journal:  Front Microbiol       Date:  2022-01-06       Impact factor: 5.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.